Biogen's commercial chief hits the road; FDA accepts Allergan's Dalvance sNDA;

@FiercePharma: A U.S. nonprofit says it has a better way to make generic drugs. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Sanofi's Kansas City, MO plant back on the block as its August 2016 closing looms. FiercePharmaManufacturing report | Follow @EricPFierce

@CarlyHFierce: Found this today on the futile hunt for things to write about. Five songs about #pharma. More #Friday | Follow @CarlyHFierce

> Biogen commercial chief Tony Kingsley is departing the company. Release

> The FDA has accepted Allergan's application to expand the label of Dalvance to include the treatment of acute bacterial skin and skin structure infections in adults. Release

> UCB is planning to seek European approval for epilepsy med Vimpat as a monotherapy during the first half of next year. Report

> Presidential hopeful Bernie Sanders (D-VT) plans to oppose U.S. President Barack Obama's nominee for FDA Commissioner, Robert Califf. Report

Medical Device News

@FierceMedDev: ICYMI: GE Ventures reaffirms commitment to VC with med tech startup program. Article | Follow @FierceMedDev

@VarunSaxena2: #AdvaMed15: CMS has 30 people to evaluate 30,000 diagnostic tests, but more FDA oversight is likely. More | Follow @VarunSaxena2

@EmilyWFierce: CalTech team creates one-time contraceptive vaccine for feral animals. More from FierceAnimalHealth | Follow @EmilyWFierce

> Procyrion raises $10M to get minimally invasive, mini heart pump in the clinic. More

> Zoll completes rollout of the sole CPR device indicated for sudden cardiac arrest. News

Biotech News

@FierceBiotech: Roche looks to shake up the MS market with some promising Phase III data. Report | Follow @FierceBiotech

@JohnCFierce: Westphal's Verastem slashes staff in the wake of a clinical trial flop. News | Follow @JohnCFierce

> Lilly upgrades its NYC research hub, adding 50 jobs in an immuno-oncology push. Story

> Roche picks up a new autoimmune drug with $580M Adheron deal. Report

And Finally... High cancer drug prices in China are creating a lucrative market in Hong Kong. More

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.